Risk model for overall survival for patients with relapsed/refractory chronic lymphocytic leukemia: Validated for patients on ibrutinib, idelalisib, venetoclax, or chemoimmuniotheraphy Meeting Abstract

  

Authors:	Soumerai, J. D.; Ni, A.; Darif, M.; Londhe, A.; Xing, G.; Mun, Y.; Kay, N. E.; Shanafelt, T. D.; Chaffee, K. G.; Furman, R. R.; Hillmen, P.; Sharman, J.; Seymour, J. F.; Chanan-Khan, A. A.; Byrd, J. C.; Jones, J. A.; Ferrante, L. A.; Dreiling, L. K.; Mobasher, M.; Stark, T.; Reddy, V.; Howes, A. J.; James, D.; Bhargava, P.; Zelenetz, A. D.
Abstract Title:	Risk model for overall survival for patients with relapsed/refractory chronic lymphocytic leukemia: Validated for patients on ibrutinib, idelalisib, venetoclax, or chemoimmuniotheraphy
Meeting Title:	60th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	132
Issue:	Suppl. 1
Meeting Dates:	2018 Dec 1-4
Meeting Location:	San Diego, CA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2018-11-29
Language:	English
ACCESSION:	WOS:000454842804063
PROVIDER:	wos
DOI:	10.1182/blood-2018-99-112989
Notes:	Meeting Abstract: 4394 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/143233